Compare INDI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | ABUS |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.0M | 848.8M |
| IPO Year | 2021 | 2008 |
| Metric | INDI | ABUS |
|---|---|---|
| Price | $4.06 | $4.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $6.25 | $5.00 |
| AVG Volume (30 Days) | ★ 5.7M | 1.3M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.95 | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $217,394,000.00 | $14,083,000.00 |
| Revenue This Year | $25.54 | N/A |
| Revenue Next Year | $38.45 | $239.71 |
| P/E Ratio | ★ N/A | $5.00 |
| Revenue Growth | 0.33 | ★ 128.21 |
| 52 Week Low | $2.32 | $3.04 |
| 52 Week High | $6.05 | $5.10 |
| Indicator | INDI | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 44.01 |
| Support Level | $4.03 | $4.16 |
| Resistance Level | $4.11 | $4.63 |
| Average True Range (ATR) | 0.41 | 0.19 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 18.98 | 26.03 |
Indie Semiconductor Inc caters to the autotech industry with semiconductors, photonics, and software platforms. The company's products include devices for a multitude of automotive applications spanning vision and radar processors, in-cabin wireless charging and USB power delivery, device interfacing through Apple CarPlay and Android Auto, and high-speed video and data connectivity. New products under evaluation or development include LiDAR, cybersecurity-enabled microcontrollers, and sensor-fusion processors. Its Photonics division mainly offers low-noise lasers, standard, and custom light sources. Geographically, the company generates the majority of its revenue from Greater China and the rest from the United States, Europe, South Korea, and other regions.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.